Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role Ms. Cote to help drive the strategic positioning of Vistagen’s clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders SOUTH SAN FRANCISCO, Calif. / Jun 25, 2025 / Business Wire / Vistagen... Read More

Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders SOUTH SAN FRANCISCO, Calif. / Jun 17, 2025 /... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 12, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to... Read More

Company’s PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026 SOUTH SAN FRANCISCO, Calif. / Jun 02, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing... Read More

SOUTH SAN FRANCISCO, Calif. / May 28, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at Jefferies 2025 Global Life Sciences Conference in New York. Vistagen’s President and Chief Executive Officer,... Read More

Posters Highlight New Insights into Social Anxiety Disorder and the Novel Mechanism of Action of Itruvone to Treat Major Depressive Disorder SOUTH SAN FRANCISCO, Calif. / May 23, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today... Read More

New Data Build on Recent Epidemiology Findings Presented by the Company at the 2024 Neuroscience Education Institute Congress The Need for Improved Diagnosis and Treatment Options Underscored by Data Presented in Posters SOUTH SAN FRANCISCO, Calif. / Apr 17, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and... Read More

Posters Highlight New Insights into Social Anxiety Disorder SOUTH SAN FRANCISCO, Calif. / Mar 19, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 04, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel’s 2025 Virtual CNS Forum. Vistagen’s President and Chief Executive Officer, Shawn Singh,... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 20, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present at the 45th Annual TD Cowen Healthcare Conference . Vistagen’s President and Chief Executive Officer, Shawn Singh, will present a... Read More

Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications SOUTH SAN FRANCISCO, Calif. / Feb 13, 2025... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 06, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 05, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that the U.S. Patent and Trademark Office (USPTO) granted a patent to the Company for its oral non-opioid product candidate, AV-101, for the treatment of... Read More

PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive efficacy signal SOUTH SAN FRANCISCO, Calif. / Jan 14, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive... Read More

All planned clinical studies in fasedienol U.S. registration-directed Phase 3 program for the acute treatment of social anxiety disorder are underway SOUTH SAN FRANCISCO, Calif. / Jan 10, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol,... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 14, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief... Read More

Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and underway SOUTH SAN FRANCISCO, Calif. / Nov 07, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 05, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 01, 2024 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide... Read More

Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join forces to raise awareness around the roles of mindfulness and pioneering neuroscience in mental health SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif. / Oct 09, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage... Read More

Next step in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder achieved as planned SOUTH SAN FRANCISCO, Calif. / Sep 23, 2024 / Business Wire / Vistagen (Nasdaq: VTGN) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain... Read More

PALISADE Phase 3 Program for the acute treatment of Social Anxiety Disorder progressing on track SOUTH SAN FRANCISCO, Calif. / Aug 13, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 06, 2024 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Tuesday, August 13, 2024, at 2:00 p.m. Pacific... Read More

SOUTH SAN FRANCISCO, Calif. / Jul 09, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global intellectual property portfolio after receiving multiple new patents... Read More

Mental Health America’s highest national certification enhances Vistagen’s ongoing efforts to promote mental health throughout the U.S. SOUTH SAN FRANCISCO, Calif. / Jun 27, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on... Read More

Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder progressing on track PALISADE-3 Phase 3 trial recently initiated; PALISADE-4 Phase 3 trial initiation anticipated in 2H 2024 SOUTH SAN FRANCISCO, Calif. / Jun 11, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 07, 2024 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its... Read More

SOUTH SAN FRANCISCO, Calif. / May 29, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Jefferies Global Healthcare Conference taking place June 5 and 6, 2024 in... Read More

SOUTH SAN FRANCISCO, Calif. / May 23, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in Phase 3 development for the acute treatment of social... Read More

SOUTH SAN FRANCISCO, Calif. / May 07, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14 and 15, 2024 in New... Read More

PH15 nasal spray demonstrates statistically significant efficacy versus placebo and caffeine in a placebo-controlled Phase 2A pilot study in sleep-deprived participants PH15 was safe and well-tolerated with an adverse event profile similar to placebo SOUTH SAN FRANCISCO, Calif. / Apr 25, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 09, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute... Read More

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder Social anxiety disorder affects over 25 million Americans SOUTH SAN FRANCISCO, Calif. / Apr 01, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 11, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024. Stifel 2024 Virtual CNS Days... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 28, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44 th Annual Health Care Conference in Boston, Massachusetts, March 4 to 6, 2024. TD... Read More

Fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder remains on track PALISADE-3 trial initiation anticipated in 1H 2024; PALISADE-4 trial initiation anticipated in 2H 2024 SOUTH SAN FRANCISCO, Calif. / Feb 13, 2024 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 06, 2024 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 third... Read More

Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101’s robust effects similar to gabapentin but with a better side effect profile Phase 1 data demonstrate AV-101 is well-tolerated, with no meaningful difference in adverse events between AV-101 and placebo at any dose tested SOUTH SAN FRANCISCO, Calif. / Dec 27, 2023 / Business Wire /... Read More

Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results Preparations to initiate potential fasedienol NDA-enabling Phase 3 studies in 2024 underway Itruvone (PH10) staged for potential Phase 2B clinical development 2H 2024 PH80 positive exploratory Phase 2A trial data reported in two separate women’s health indications –... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 08, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings at the Stifel 2023 Healthcare Conference taking place November 14 –... Read More

Positive top-line results from fasedienol (PH94B) Phase 3 PALISADE-2 trial in social anxiety disorder (SAD) to be presented by SAD expert, Dr. Michael Liebowitz, at CNS Summit 2023 Positive results from PH80 Phase 2A study in women diagnosed with vasomotor symptoms (hot flashes) due to menopause to be presented at the 2023 Neuroscience Education Institute (NEI) Congress SOUTH SAN FRANCISCO, Calif. / Nov 07, 2023 / Business... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 06, 2023 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to provide... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 05, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the Company will present and host one-on-one meetings at the Jefferies Biotech CNS/Neuro Summit taking place October 11 – 12, 2023... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 02, 2023 / Business Wire / Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its common stock (or pre-funded warrants to... Read More

PH80 nasal spray demonstrated statistically and clinically significant improvement versus placebo in an exploratory double-blind, placebo-controlled Phase 2A study (n=52) in subjects with a history of premenstrual dysphoric disorder (PMDD) PH80 was well-tolerated with an adverse event profile similar to placebo Data builds on the previously reported vasomotor symptoms (hot flashes) due to menopause study, reinforcing the... Read More

Vistagen to receive $1.5 million and Fuji to obtain time-limited exclusive negotiation period for the Japanese market Recently reported exploratory Phase 2A study in women diagnosed with menopausal hot flashes demonstrated PH80’s statistically significant reduction in the number of hot flashes and the severity, disruption in function, and sweating related to hot flashes as compared with placebo SOUTH SAN FRANCISCO, Calif. &... Read More

Anderson succeeds Jerrold Dotson who is retiring after a distinguished decade-long career with Vistagen SOUTH SAN FRANCISCO, Calif. / Aug 22, 2023 / Business Wire / Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson... Read More

Positive top-line results from Phase 3 PALISADE-2 trial of rapid-onset fasedienol (PH94B) nasal spray in social anxiety disorder (SAD) Itruvone (PH10) nasal spray now staged for Phase 2B clinical development as a stand-alone, non-systemic treatment for major depressive disorder (MDD) Positive exploratory Phase 2A trial of PH80 nasal spray provides new optimism for the acute treatment of moderate to severe vasomotor symptoms... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 08, 2023 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to provide a... Read More

First positive U.S. Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years Statistically significant rapid-onset reduction in patient-reported Subjective Units of Distress Scale (SUDS) score compared to placebo in a public speaking challenge (primary endpoint, p=0.015) Trial also met the secondary endpoint, demonstrating a statistically significant reduction in proportion of responders... Read More

Preclinical study of radiolabeled intranasal itruvone in laboratory rats further validates itruvone’s potential to treat major depressive disorder (MDD) without systemic absorption SOUTH SAN FRANCISCO, Calif. / Jul 17, 2023 / Business Wire / Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central... Read More

Oral levodopa is the gold standard treatment for motor symptoms in individuals diagnosed with Parkinson’s disease, despite the risk of dyskinesia (sudden uncontrolled movements) related to long-term use of levodopa Published preclinical data in widely used MPTP non-human primate model of Parkinson's disease show AV-101 reduced levodopa-induced dyskinesias without adverse side effects often observed with amantadine therapy,... Read More

Positive results in Phase 3 open label study of fasedienol (PH94B) in social anxiety disorder (SAD) Positive U.S. Food and Drug Administration (FDA) feedback on the use of the Liebowitz Social Anxiety Scale (LSAS) as the primary efficacy endpoint in future Phase 3 studies of fasedienol in SAD Successful itruvone (PH10) U.S. Phase 1 study supports previous successful Phase 1 studies and a positive Phase 2A study in major... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 27, 2023 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Wednesday, June 28, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to report results... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 23, 2023 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that, on June 22, 2023, Vistagen received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (Nasdaq)... Read More

The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and tolerability profile across single and multiple dose intranasal administrations SOUTH SAN FRANCISCO, Calif. / Jun 21, 2023 / Business Wire / Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 16, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in the Healthcare Virtual Conference presented by Maxim Group LLC taking... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 13, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of... Read More

PH80 nasal spray demonstrates statistically significant efficacy versus placebo in exploratory double-blind, placebo-controlled Phase 2A study (n=36) in women diagnosed with menopausal hot flashes PH80 was safe and well-tolerated with an adverse event profile similar to placebo SOUTH SAN FRANCISCO, Calif. / Jun 07, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 06, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 06, 2023 / Business Wire / Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty... Read More

Favorable long-term, open-label treatment data from nearly 500 patients in real-world setting suggest that patient-tailored, as-needed administrations of fasedienol over time were safe and well-tolerated Positive exploratory fasedienol efficacy data measured by the Liebowitz Social Anxiety Scale (LSAS) demonstrated clinically meaningful reductions in fear, anxiety and avoidance of anxiety-provoking social and performance... Read More

Late-breaking poster presentation highlights long-term, open-label treatment data of as-needed intranasal administrations of fasedienol in real-world setting SOUTH SAN FRANCISCO, Calif. / May 30, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS)... Read More

Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S. Timely recognition comes during Mental Health Awareness Month and MHA’s nationwide efforts to fight stigma and provide support around mental health SOUTH SAN FRANCISCO, Calif. / May 24, 2023 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company... Read More

Results from new study further support that fasedienol acts locally in the nasal passages and does not require systemic uptake or direct activity on neurons in the brain to achieve fast-acting anti-anxiety effects SOUTH SAN FRANCISCO, Calif. / Apr 19, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety,... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 06, 2023 / Business Wire / Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) has granted the Company a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine... Read More

Vistagen plans to use the LSAS as the primary efficacy endpoint for a Phase 3 clinical study designed to evaluate fasedienol as a treatment for the overall control of symptoms of social anxiety disorder (SAD) FDA provides helpful guidance on key aspects of potential NDA-enabling development plan in SAD SOUTH SAN FRANCISCO, Calif. / Mar 30, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage... Read More

Long-term intranasal administration of fasedienol, used as-needed up to four times a day in daily life, was safe and well-tolerated in nearly 500 patients with social anxiety disorder (SAD) Patients self-administered over 30,000 doses of fasedienol in real-world settings, with a mean study duration of 4 months, and a maximum study duration of over 10 months Fasedienol demonstrated clinically meaningful reductions in fear,... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 01, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a U.S. patent for Vistagen’s PH80 nasal spray for treatment of migraine.... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 07, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022. “Since our last... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 06, 2023 / Business Wire / Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Tuesday, February 7, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report... Read More

Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen's pipeline SOUTH SAN FRANCISCO, Calif. / Feb 02, 2023 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its... Read More

Small U.S. Phase 1 trial with newly optimized formulation to confirm favorable safety profile from three previous clinical trials and facilitate Phase 2B development of PH10 as a stand-alone treatment for major depressive disorder SOUTH SAN FRANCISCO, Calif. / Jan 24, 2023 / Business Wire / Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals... Read More

In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major Depressive Disorder (MDD). The trial, involving the Company’s newly optimized formulation of PH10, is intended to confirm the favorable safety profile of PH10 established in three previous clinical studies conducted in Mexico,... Read More

Topline results of the exploratory Phase 2 clinical study anticipated in Q1 2023 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the last patient has completed the study protocol in its Phase 2 clinical trial of PH94B for the treatment of... Read More

Vistagen’s recent patent filings in the U.S. and numerous additional countries mark the next step in the Company’s ongoing efforts to enhance potential commercial protection across its CNS pipeline in key pharmaceutical markets Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system... Read More

Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Pherin... Read More

The Fast Track designation may expedite development of PH10 for treatment of major depressive disorder in adults SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the U.S. Food and Drug... Read More